Efficacy of the neurokinin-1 receptor antagonist rolapitant(VARUBI) in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy - Hesketh - 2016 - Cancer - Wiley Online Library Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, May 13, 2016

Efficacy of the neurokinin-1 receptor antagonist rolapitant(VARUBI) in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy - Hesketh - 2016 - Cancer - Wiley Online Library



Blogger's Note: ovarian cancer patients were included in this study

Rolapitant (VARUBI®

open access - Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy

Study Design and Patients

A global, multicenter, randomized, parallel-group, double-blind, controlled phase 3 study (NCT01500226) was conducted in 23 countries in North America, Central and South America, Europe, Asia, and Africa.[12] The protocol was approved by institutional review boards at each study site, all patients provided written informed consent, and all investigators and site personnel were required to follow ethical principles outlined in the Declaration of Helsinki and consistent with the International Conference on Harmonisation Good Clinical Practice guidelines and applicable local laws and regulations.

Patients (see Table1)

Of the 1332 patients who composed the modified intent-to-treat population for the phase 3 MEC trial, 401 received their first course of chemotherapy with a carboplatin-based regimen and were included in the efficacy analysis for cycle 1. Baseline and disease characteristics were similar for patients in the rolapitant and control groups, as shown in Table 1. The median age of the patients was 62 years, and more patients were female (54.9%) than male (45.1%). The primary malignancy among patients treated with carboplatin-based chemotherapy was lung cancer (52.1%); other malignancies included ovarian, breast, and uterine cancer (13.7%, 13.7%, and 7.7%, respectively). The receipt of concomitant emetogenic chemotherapy with a Hesketh level ≥ 3 was low and occurred in 15.7% of the patients.

CONCLUSIONS

Rolapitant provided superior CINV protection to patients receiving carboplatin-based chemotherapy in comparison with the control. These results support rolapitant use as part of the antiemetic regimen in carboplatin-treated patients.

FUNDING SUPPORT 

CONFLICT OF INTEREST DISCLOSURES 



0 comments :

Post a Comment

Your comments?